Kratom and 7-OH Drug Testing: What Employers and Treatment Programs Should Know in 2026
What Kratom Is — and Why It Matters for Drug Testing Programs
Kratom (Mitragyna speciosa) is a plant native to Southeast Asia whose leaves contain alkaloids — most notably mitragynine and its metabolite 7-hydroxymitragynine (7-OH) — that interact with opioid receptors in the brain. At low doses, kratom produces stimulant-like effects. At higher doses, its effects resemble those of opioid drugs — pain relief, sedation, and euphoria. 7-OH, the primary active metabolite, is substantially more potent than mitragynine at opioid receptors.
Kratom is sold legally in most U.S. states as a dietary supplement, often in powder, capsule, or liquid extract form, under product names that do not mention the word kratom or reference any drug-like effect. It is widely available at gas stations, smoke shops, and online retailers. Its legal status has contributed to its growing use as a self-managed substitute for opioids in some recovery contexts — and to its increasing presence in populations that drug testing programs are designed to monitor.
The U.S. Food and Drug Administration (FDA) has raised ongoing concerns about kratom, noting that it has opioid-like properties and poses risks including abuse, addiction, and in some cases serious adverse events. The FDA has not approved kratom for any medical use and has taken regulatory action on kratom products making drug claims. For testing programs, the FDA's public health position reinforces why kratom — despite its legal status in most states — warrants specific screening protocols in recovery, corrections, and workplace settings.
Why 7-OH Is the More Important Target
7-hydroxymitragynine (7-OH) is the principal active metabolite produced when the body processes mitragynine. Research has established that 7-OH has substantially greater potency at mu-opioid receptors than mitragynine itself — some estimates place it at significantly higher binding affinity than morphine. This pharmacological profile is why 7-OH is associated with the opioid-like effects of kratom at higher doses, and why high-potency kratom products — particularly liquid extracts marketed as "kratom shots" or "7-OH extract" — have attracted attention from addiction medicine specialists and regulatory agencies.
For testing purposes, a kratom-specific assay that targets mitragynine at a defined cutoff level will detect kratom use in urine. The SAFElife 1 Panel Kratom T-Dip Dip Card is calibrated at a 300 ng/mL cutoff for KRA (mitragynine) — the same compound that 7-OH is metabolized from. Detecting mitragynine in urine is the standard approach for point-of-care kratom screening because mitragynine is excreted in urine at significantly higher concentrations than 7-OH.
Who Should Be Testing for Kratom
Kratom testing is most relevant for three buyer categories: addiction treatment and recovery programs, corrections and probation, and employers with substance-free workplace policies that explicitly address kratom or novel psychoactive substances.
Kratom Testing — Priority Program Types
- Addiction treatment and recovery programs: Kratom is sometimes used as a self-managed opioid substitute — residents or patients in MAT programs, sober living homes, or residential treatment may be using kratom while appearing clean on standard screens. Given the FDA's documented concerns about kratom's opioid-like properties and its potential for abuse and dependence, recovery programs and sober living facilities serving opioid use disorder populations should evaluate whether their current panels address kratom explicitly
- Corrections and probation: Courts and probation offices that require substance-free conditions of supervision are increasingly encountering kratom use. Because kratom is legal and not detected on standard panels, individuals under supervision may use it without triggering a positive result — undermining the purpose of a substance-free supervision requirement
- Sober living and recovery residences: NARR-aligned and Oxford House recovery residences that operate under substance-free policies should consider whether their current testing panels address kratom explicitly — particularly in populations with opioid use disorder histories where kratom use as a substitute is documented
- Employers with explicit substance-free policies: Employers whose written drug-free workplace policy prohibits all intoxicating substances — not just federally scheduled drugs — should evaluate whether their panel configuration addresses kratom if it is a known issue in their workforce population
The Three Testing Options at DrugScreens.com
DrugScreens.com carries three SAFElife products for programs that need kratom detection capability — a dedicated single-panel kratom dip card for add-on screening, a CLIA-waived 14-panel cup for programs that need CLIA documentation, and an 18-panel Forensic Use cup that includes kratom alongside fentanyl, EtG, tramadol, K2, and the full standard panel. Classification matters — read the badges carefully.
1 Panel Kratom T-Dip Dip Card · 300ng/mL
Single-panel kratom dip card. Targets mitragynine at 300 ng/mL cutoff. Forensic Use. Use as an add-on screen alongside any existing cup program. 25 cards per box · $100.00.
Shop Kratom Dip Card14 Panel C-Cup — FTY Included
14-panel CLIA-waived cup with fentanyl detection. CLIA Waived. When CLIA-waived documentation is required for Medicaid billing or program compliance — the broadest CLIA-waived panel available.
Shop 14 Panel Cup18 Panel C-Cup — EtG + FTY + TRA + K2 + Kratom
Broadest panel available. Includes kratom (KRA250), fentanyl, EtG alcohol, tramadol, K2, plus full standard panel. Forensic Use. 25 cups per box · $143.00. Best for high-acuity recovery programs and corrections.
Shop 18 Panel CupThe 18-panel cup tests for what programs are actually seeing in 2026.
Classification Guide — CLIA Waived vs. Forensic Use
The kratom dip card and the 18-panel cup are both classified as Forensic Use. The 14-panel cup is CLIA Waived. This distinction matters for programs that require CLIA-waived devices for Medicaid billing, OhioMHAS compliance documentation, or other regulatory reporting purposes.
Building a Kratom-Aware Testing Protocol
Programs that want to address kratom in their testing framework have two practical approaches: add a dedicated single-panel kratom dip card as a supplemental screen alongside an existing cup program, or upgrade to the 18-panel cup that includes kratom as one of its 18 analytes. The right choice depends on budget, testing volume, required CLIA status, and whether kratom is a known issue in the specific population being served.
Kratom Testing Protocol Decision Guide
- If you need CLIA-waived documentation AND kratom screening: Use the 14-panel CLIA-waived cup for Medicaid-documented tests, plus the 1-panel kratom T-Dip as a supplemental Forensic Use screen on the same specimen
- If CLIA status is not required for your kratom screens: The 18-panel Forensic Use cup provides kratom, fentanyl, EtG, tramadol, K2, and the full standard panel in a single all-in-one collection device
- If you want to add kratom detection to an existing cup program without changing cups: The 1-panel kratom T-Dip dip card can be run on the same urine specimen alongside any other cup — no additional collection required
- Confirm all non-negatives: All three SAFElife kratom-screening products provide presumptive results — any presumptive positive used for a clinical or program-exit decision should be confirmed by a certified laboratory
- Update your written policy: If your program policy does not currently reference kratom explicitly, adding kratom to the list of prohibited substances before implementing kratom testing is an important documentation step
This content is provided for general informational purposes only and does not constitute legal advice. Any employer or organization considering changes to its workplace or in-house drug screening policies should consult with qualified legal counsel and applicable regulatory authorities before implementing, modifying, or discontinuing any testing program or related procedures.
